PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
MCRB vs. PALI
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Correlation

The correlation between MCRB and PALI is 0.15, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.


-0.50.00.51.00.2

Performance

MCRB vs. PALI - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Seres Therapeutics, Inc. (MCRB) and Palisade Bio, Inc. (PALI). The values are adjusted to include any dividend payments, if applicable.

-100.00%-80.00%-60.00%-40.00%-20.00%0.00%20.00%40.00%SeptemberOctoberNovemberDecember2025February
-7.69%
-100.00%
MCRB
PALI

Key characteristics

Sharpe Ratio

MCRB:

-0.19

PALI:

-0.70

Sortino Ratio

MCRB:

0.57

PALI:

-1.71

Omega Ratio

MCRB:

1.07

PALI:

0.79

Calmar Ratio

MCRB:

-0.23

PALI:

-0.86

Martin Ratio

MCRB:

-0.60

PALI:

-1.52

Ulcer Index

MCRB:

37.88%

PALI:

56.45%

Daily Std Dev

MCRB:

119.13%

PALI:

122.16%

Max Drawdown

MCRB:

-98.93%

PALI:

-100.00%

Current Drawdown

MCRB:

-98.44%

PALI:

-100.00%

Fundamentals

Market Cap

MCRB:

$137.19M

PALI:

$2.80M

EPS

MCRB:

-$0.40

PALI:

-$13.26

Total Revenue (TTM)

MCRB:

$0.00

PALI:

$0.00

Gross Profit (TTM)

MCRB:

-$2.98M

PALI:

-$2.00K

EBITDA (TTM)

MCRB:

-$111.55M

PALI:

-$11.08M

Returns By Period

In the year-to-date period, MCRB achieves a -3.31% return, which is significantly higher than PALI's -42.84% return.


MCRB

YTD

-3.31%

1M

-11.85%

6M

-7.72%

1Y

-26.95%

5Y*

-26.84%

10Y*

N/A

PALI

YTD

-42.84%

1M

-34.04%

6M

-72.50%

1Y

-85.12%

5Y*

-81.42%

10Y*

-75.11%

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Risk-Adjusted Performance

MCRB vs. PALI — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

MCRB
The Risk-Adjusted Performance Rank of MCRB is 3939
Overall Rank
The Sharpe Ratio Rank of MCRB is 3737
Sharpe Ratio Rank
The Sortino Ratio Rank of MCRB is 4848
Sortino Ratio Rank
The Omega Ratio Rank of MCRB is 4747
Omega Ratio Rank
The Calmar Ratio Rank of MCRB is 3333
Calmar Ratio Rank
The Martin Ratio Rank of MCRB is 3434
Martin Ratio Rank

PALI
The Risk-Adjusted Performance Rank of PALI is 66
Overall Rank
The Sharpe Ratio Rank of PALI is 1212
Sharpe Ratio Rank
The Sortino Ratio Rank of PALI is 33
Sortino Ratio Rank
The Omega Ratio Rank of PALI is 55
Omega Ratio Rank
The Calmar Ratio Rank of PALI is 33
Calmar Ratio Rank
The Martin Ratio Rank of PALI is 55
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

MCRB vs. PALI - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for Seres Therapeutics, Inc. (MCRB) and Palisade Bio, Inc. (PALI). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


Sharpe ratio
The chart of Sharpe ratio for MCRB, currently valued at -0.19, compared to the broader market-2.000.002.00-0.19-0.70
The chart of Sortino ratio for MCRB, currently valued at 0.57, compared to the broader market-4.00-2.000.002.004.006.000.57-1.71
The chart of Omega ratio for MCRB, currently valued at 1.07, compared to the broader market0.501.001.502.001.070.79
The chart of Calmar ratio for MCRB, currently valued at -0.23, compared to the broader market0.002.004.006.00-0.23-0.86
The chart of Martin ratio for MCRB, currently valued at -0.60, compared to the broader market-10.000.0010.0020.0030.00-0.60-1.52
MCRB
PALI

The current MCRB Sharpe Ratio is -0.19, which is higher than the PALI Sharpe Ratio of -0.70. The chart below compares the historical Sharpe Ratios of MCRB and PALI, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Rolling 12-month Sharpe Ratio-0.70-0.60-0.50-0.40-0.30-0.20-0.10SeptemberOctoberNovemberDecember2025February
-0.19
-0.70
MCRB
PALI

Dividends

MCRB vs. PALI - Dividend Comparison

Neither MCRB nor PALI has paid dividends to shareholders.


Tickers have no history of dividend payments

Drawdowns

MCRB vs. PALI - Drawdown Comparison

The maximum MCRB drawdown since its inception was -98.93%, roughly equal to the maximum PALI drawdown of -100.00%. Use the drawdown chart below to compare losses from any high point for MCRB and PALI. For additional features, visit the drawdowns tool.


-100.00%-99.50%-99.00%-98.50%-98.00%SeptemberOctoberNovemberDecember2025February
-98.44%
-100.00%
MCRB
PALI

Volatility

MCRB vs. PALI - Volatility Comparison

The current volatility for Seres Therapeutics, Inc. (MCRB) is 10.55%, while Palisade Bio, Inc. (PALI) has a volatility of 16.12%. This indicates that MCRB experiences smaller price fluctuations and is considered to be less risky than PALI based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


10.00%20.00%30.00%40.00%50.00%60.00%70.00%SeptemberOctoberNovemberDecember2025February
10.55%
16.12%
MCRB
PALI

Financials

MCRB vs. PALI - Financials Comparison

This section allows you to compare key financial metrics between Seres Therapeutics, Inc. and Palisade Bio, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


Values in USD except per share items
PortfoliosLab logo
Performance Analysis
Portfolio AnalysisPortfolio PerformanceStock ComparisonSharpe RatioMartin RatioTreynor RatioSortino RatioOmega RatioCalmar RatioSummers Ratio
Community
Discussions


Disclaimer

The information contained herein does not constitute investment advice and made available for educational purposes only. Prices and returns on equities are listed without consideration of fees, commissions, taxes, penalties, or interest payable due to purchasing, holding, or selling.

Copyright © 2025 PortfoliosLab